Oestradiol (E 2 ) accelerates oviductal transport of oocytes in cycling rats through a nongenomic pathway that involves the cAMP-PKA signalling cascade. Here we examined the role of the inositol triphosphate (IP3) and mitogen-activated protein kinase (MAPK) signalling cascades in this nongenomic pathway. Oestrous rats were injected with E 2 s.c. and intrabursally (i.b) with the selective inhibitors of phospholipase C (PLC) ET-18-OCH 3 or MAPK PD98059. The number of eggs in the oviduct assessed 24 h later showed that ET-18-OCH 3 blocked E 2 -induced egg transport acceleration, whereas PD98059 had no effect. Other oestrous rats were treated with E 2 s.c. and 1, 3 or 6 h later oviducts were excised and the levels of IP3 and phosphorylated MAPK p44/42 (activated) were determined by radioreceptor assay and western blot, respectively. Oestradiol administration increased IP3 level at 1 and 6 h after treatment, whereas activated MAPK p44/42 level was unchanged. Finally, we explored whether cAMP-PKA and PLC-IP3 signalling cascades are coupled. Inhibition of adenylyl cyclase by i.b. injection of SQ 22536 blocked the increase of IP3 levels induced by E 2 , while inhibition of PLC by ET-18-OCH 3 had no effect on E 2 -induced PKA activity. Furthermore, activation of adenylyl cylase by Forskolin increased oviductal IP3 levels. Thus, activation of PLC-IP3 by E 2 requires previous stimulation of cAMP-PKA. We conclude that the nongenomic pathway utilised by E 2 to accelerate oviductal transport of oocytes in cycling rats involves successive activation of the cAMP-PKA and PLC-IP3 signalling cascades and does not require activation of MAPK. These findings clearly illustrate a nongenomic pathway triggered by E 2 that regulates a complex physiologic process accomplished by an entire organ.
Introduction
In the rat, the duration of oviductal egg transport is dependent on ovarian hormones and mating-associated signals (for review see Croxatto 2002) . A single injection of oestradiol (E 2 ) on day 1 of the cycle or pregnancy shortens oviductal transport of eggs from the normal 72-96 h to less than 24 h (Ortiz et al. 1979 ).
The classical model of E 2 action on its target cells comprises its binding to oestrogen receptors (ER), leading to modification of gene expression and protein synthesis (Nilsson et al. 2001) . However, this model cannot explain the E 2 effects that are not blocked by inhibitors of transcription or translation, or are too rapid to be due to changes in gene expression. Therefore, these effects have been named nongenomic (Lössel & Wheling 2003 , Lössel et al. 2003 . The nongenomic actions of E 2 often involve the generation of intracellular secondary messengers, and various signal transduction cascades upon binding to ER (Nadal et al. 2001) .
Activation of signal transduction cascades by E 2 modulates diverse downstream pathways that have discrete cellular actions, including stimulation of adenylyl cyclase in breast and vascular tissues (Aronica et al. 1994 , Farhat et al. 1996 and phospholipase C (PLC) type in rat osteoblasts (Le Mellay et al. 1997) , generation of inositol triphosphate (IP3) in rat vaginal epithelial cells (Singh & Gupta 1997) , activation of Ca 2+ flux and Ca
2+
-activated K + channels in arterial smooth muscle (Prakash et al. 1999 , Valverde et al. 1999 , activation of cGMP-dependent protein kinase in pancreatic -cells (Ropero et al. 1999) , activation of protein kinases A (PKA) and C (PKC) in -endorphin neurons (Qiu et al. 2003) and protein phosphorylation via activation of tyrosine kinases, phospahtidyl inositol 3 kinase (PI3K) and mitogenactivated protein kinases' (MAPK) pathways in MCF-7 cells (Migliaccio et al. 2000 , Márquez & Pietras 2001 , Stoica et al. 2003 .
We previously demonstrated that RNA and protein synthesis inhibitors block E 2 -induced oviductal embryo transport acceleration in pregnant rats, but failed to do so in cyclic rats (Ríos et al. 1997 . Furthermore, in cyclic rats exogenous E 2 activates protein phosphorylation in the oviduct via a nongenomic action, since such activation occurs when mRNA synthesis is completely suppressed by -amanitin ). Oestradiol-induced phosphorylation is essential for its effect on oocyte transport in cycling rats; local administration of a broad-spectrum inhibitor of protein kinases totally blocks E 2 -induced acceleration of egg transport , ParadaBustamante et al. 2003 . Moreover, local administration of the anti-oestrogen ICI 182780 and of a selective inhibitor of adenylyl cyclase SQ22536 totally blocks egg transport acceleration induced by E 2 , whereas a PKA inhibitor Rp-cAMP only partially blocks this effect of E 2 . In addition, the adenylyl cyclase activator Forskolin mimics the effect of E 2 on egg transport . Thus, E 2 accelerates oviductal transport of oocytes via a nongenomic action that involves oviductal protein phosphorylation. The nongenomic pathway by which E 2 accelerates oviductal egg transport in the rat requires participation of ER, generation of cAMP and activation of PKA.
In this work, we explored the contribution of IP3 and MAPK signalling cascades in this nongenomic pathway. First we examined the role of IP3 and MAPK on accelerated oocyte transport induced by E 2 . The effect of E 2 on the levels of IP3 or phosphorylated MAPK p44/42 in the rat oviduct was then determined. Finally, we determined whether cAMP-PKA and PLC-IP3 signalling cascades are coupled. For this purpose, we examined the effect of a selective inhibitor of adenylyl cyclase or PLC on E 2 -induced increase of IP3 levels or PKA activity, respectively. In addition, we determined the effect of an activator of adenylyl cyclase on oviductal IP3 level.
Materials and Methods

Animals
Sprague-Dawley rats (bred in house) weighing 200-260 g were used. The animals were kept under controlled temperature (21-24 C) and lights were on from 0700 to 2100 h. Water and pelleted rat chows were supplied ad libitum. The phases of the oestrous cycle were determined by daily vaginal smears (Turner 1961) . Only rats that showed at least two regular 4-day cycles were used. The day of oestrus was considered day 1 of the cycle. The care and manipulation of the animals was made in accordance with the ethical guidelines of our institution.
Treatments
Systemic administration of drugs On day 1 of the cycle E 2 1 µg in 0·1 mL of propylene glycol or the PLC inhibitor ET-18-OCH 3 (1-O-Octadecyl-2-O-methylrac-glycero-3-phosphorylcholine; Calbiochem, La Jolla, CA, USA; Powis et al. 1992) 32 µg in 0·1 mL of saline were injected s.c. as a single dose. Control rats received the corresponding vehicle alone.
Local administration of drugs The drugs described below were injected into each ovarian bursa dissolved in the appropriate vehicle (control rats received the corresponding vehicle alone):
Adenylyl cyclase inhibitor: SQ 22536 (9-(tetrahydro-2'furyl) adenine; Calbiochem; Goldsmith & Abrams 1991) was injected as a single dose of 30 µg in 4 µL of saline solution. Previously, we have shown that this concentration completely blocks the E 2 -induced oviductal egg transport acceleration .
MAPK inhibitor: PD98059 (2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; Calbiochem; Verin et al. 2000 , Xiao et al. 2004 ) was injected as a single dose of 0·5, 5, 50 µg in 4 µL of 0·1% DMSO.
Phospholipase C inhibitor: ET-18-OCH 3 (1-OOctadecyl-2-O-methyl-rac-glycero-3-phosphorylcholine; Calbiochem; Powis et al. 1992 ) was injected as a single dose of 0·032, 0·32, 3·2 or 32 µg in 4 µL saline solution.
Adenylyl cyclase activator: Forskolin (7 -Acetoxy-8, 13-epoxy-1 ,6 ,9 -trihidroxy-labd-14-ene-11-one; Sigma Chemical Co.; Uneyama et al. 1993 ) was injected as a single dose at a concentration of 20 µg in 4 µL 0·1% DMSO.
Animal surgery
Intrabursal administration of drugs was performed in the morning of day 1 of the cycle as described by . At this time, ovulation has already taken place, so this treatment cannot affect the number of oocytes ovulated.
Assessment of egg transport
Twenty-four hours after treatment, animals were sacrificed and their oviducts were flushed individually with saline. Flushings were examined under low-power magnification ( 25). The number of eggs in the oviduct was recorded. We have previously determined from egg recovery experiments from uterus and vagina and from placing ligatures in the uterine horns that the reduction in the number of oviductal oocytes following treatment with E 2 corresponds to premature transport to the uterus (Ortiz et al. 1979) . Thus, we refer to it as E 2 -induced accelerated egg transport.
Measurement of IP3 levels
Whole oviducts in groups of four were homogenised in 0·25 mL ice cold 1 M trichloroacetic acid (TCA) and centrifuged for 10 min at 1000 g at 4 C. The pellet was discarded and the supernatant was incubated for 15 min at room temperature. TCA was removed from the supernatant with 0·5 mL of a solution comprising of a mixture of 1,1,2-Trichloro-trifluoroethane (TCTFE; Sigma) and Trioctylamine (Sigma), 3:1 (v/v 
MAPK p44/42 phosphorylation
Polyclonal antibodies that recognize the phosphorylated state of MAPK on Tyr204 (anti-phosphoMAPK p44/42, (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) or total MAPK (anti-MAPK p42, Santa Cruz Biotechnology) were used to assess activation of MAPK. Whole oviducts were removed and cleaned from fat tissue. Because we wanted to analyse only oviductal proteins, oviducts were flushed with saline in order to remove the cumulus-oocytes complex and thus avoid contamination with their proteins. Then, oviducts in groups of four (obtained from two rats) were homogenized on ice for 10 sec in 1 mL of buffer containing 0·25 mM sucrose, 3·0 mM MgCl 2 , 25 mM Tris, and 0·5 mM phenylmethylsulfonyl fluoride (Taragnat 1988) followed by centrifugation at 6000 r.p.m. for 10 min at 4 C. The supernatant (clarified homogenate) was harvested and stored at -20 C until used. The protein concentration in the clarified homogenate was determined according to Bradford (1976) using BSA as standard. Aliquots of the clarified homogenate containing 100 µg protein were denatured for 2 min at 90 C in equal volume of 0·125 M Tris-HCl (pH 6·8) containing 4% SDS, 10% -mercaptoethanol, 20% glycerol and 0·04% bromophenol blue. Samples were run on 12% SDS polyacrylamide slab gels according to the method of Laemmli (1970) utilizing a mini PROTEAN electrophoretic chamber (Bio-Rad). Proteins resolved in the gels were electroblotted onto nitrocellulose membranes (Bio-Rad; Towbin et al. 1979) . Nitrocellulose blots were blocked by incubation overnight at 4 C in TTBS (100 mM Tris/HCl (pH 7·5), 0·9% v/v 150 mM NaCl and 0·05% v/v Tween 20) containing 1% BSA and were incubated for 2 h with a rabbit anti-MAPK p44 or anti-phosphoMAPK p44/42 in 1:200 dilution. Blots were rinsed five times for 5 min each in TBS (100 mM Tris/HCl (pH 7·5), and 0·9% v/v 150 mM NaCl) and were incubated for 2 h in TTBS containing 1:5000 dilution of goat anti-rabbit IgG horseradish peroxidase conjugate (Chemicon International, Temecula, CA, USA). The horseradish peroxidase activity was detected by enhanced chemiluminescence using western Lighting Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Boston, MA, USA). Negative controls consisting of oviductal samples without anti-MAPK p44 or anti-phosphoMAPK p44/42 were included. Protein extracts of a breast cancer cell line (MCF-7, kindly donated by Gareth Owen, Pontificia Universidad Católica de Chile, Santiago, Chile) were used as positive controls.
Activity of PKA
Whole oviducts in groups of four were sonicated in sample preparation buffer (50 mM Tris-Hcl, 50 mM -mercaptoethanol, 10 mM EGTA, 5 mM EDTA, 1 mM PMSF, 10 mM Benzamidine (pH 7·5)) and centrifuged for 5 min at 10000 g. Aliquots of the supernatant (100 µg) were used to determine PKA activity with a Protein Kinase Assay Kit, Non-Radioactive, catalogue no. 538484, lot number B31285 (Calbiochem). This kit provides an enzyme-linked immunosorbent assay that utilizes a synthetic PKA substrate peptide and a monoclonal biotinylated antibody that recognizes the phosphorylated form of the peptide. Colour was developed with peroxidase-conjugated streptavidin and ophenylenediamine as substrate. Optical density was read at 492 nm, with a microplate reader (BIO-TEK Instruments Inc., Winooski, VT, USA). A standard curve using 1-100 mU bovine heart PKA (Sigma; specific activity: 1-2 units/µg protein) was constructed to determine the PKA activity in the unknown samples. Although we used bovine heart PKA instead of rat PKA the homology between these enzymes is highly conserved (Titani et al. 1984 , Kuno et al. 1987 ), therefore we extrapolated data obtained from the bovine PKA to our rat model.
Activity of MAPK
Whole oviducts in groups of four were homogenized in RIPA buffer (50 mM Tris-Hcl (pH 8·0), 150 mM NaCl, 0·5 mM EDTA, 1 mM DDT, 1% NP-40, 0·5% Sodium Deoxycholate, 0·1% SDS and protease inhibitors cocktail) and centrifuged for 10 min at 12000 g. Aliquots of the supernatant (150 µg) were used to determine MAPK activity with a MAP Kinase (ERK1/2) Activity Assay Kit, catalogue number SGT415, lot number 0606002744 (Chemicon). This kit provides an enzyme-linked immunosorbent assay that utilizes a biotinylated synthetic MAPK substrate peptide (myelin basic protein -MBP). The fraction of phosphorylated substrate is visualized using a phospho-MBP monoclonal antibody and a horseradish peroxidase conjugated secondary antibody and an ensuing chromogenic substrate reaction. Optical density was read at 450 nm with a microplate reader (BIO-TEK Instruments Inc.).
Statistical Analysis
The results are presented as mean S.E.M. Overall analysis was done by Kruskal-Wallis test, followed by MannWhitney test for pair-wise comparisons when overall significance was detected. The actual number of replicates (n) in experiments done to determine IP3 levels, MAPK and PKA activity in the rat oviduct corresponds to three or four replicates. In each replicate, two rats for each treatment group were used and the four oviducts of these two animals were homogenised as a pool to determine IP3 levels and PKA activity. The actual n in experiments done to determine the effect of drugs on oviductal egg transport is the total number of rats used in each experimental group, because the total number of eggs recovered from the two oviducts of a single rat corresponds to a single data point.
Results
Effect of local treatment with specific signalling pathway inhibitors on E 2 -induced egg transport acceleration
Two experiments were performed to determine whether local administration of selective MAPK (PD98059) or PLC-IP3 (ET-18-OCH 3 ) signalling inhibitors can prevent the acceleration of oviductal egg transport induced by E 2 in cycling rats. A total of 60 animals on day 1 of the cycle were used and, for each experiment, they were divided into the following treatment groups: 1) vehicle plus propylene glycol; 2) PD98059 (50 µg) or ET-18-OCH 3 (32 µg) plus propylene glycol; 3) vehicle plus E 2 and 4) PD98059 (0·5, 5 or 50 µg) or ET-18-OCH 3 (0·032, 0·32, 3·2 or 32 µg) plus E 2 . Twenty-four hours after treatment, egg transport was assessed as described. Replicas of this experiment are stated in Figure 1 .
The results are shown in Figure 1 . The mean number of eggs recovered from the oviducts of control groups ranged from 9·3 1·3 to 8·3 0·7, while in groups treated with E 2 it ranged from 0·8 0·3 to 0·5 0·2. Local administration of inhibitors alone did not affect oviductal egg recovery (range 8·2 1·1 to 7·9 1·3). The PLC inhibitor blocked the E 2 -induced oviductal egg transport acceleration in a dose-dependent manner (1·0 0·6 to 9·0 0·7) while the MAPK inhibitor had no effect (range 1·0 0·7 to 2·2 1·7).
Effect of systemic administration of ET-18-OCH 3 on E 2 -induced egg transport acceleration
Since local administration of ET-18-OCH 3 inhibited the effect of E 2 on egg transport, this experiment was done to rule out that the effect was systemic rather than local. A total of 11 rats were divided into the following treatment groups: 1) vehicle plus propylene glycol; 2) vehicle plus E 2 and 3) ET-18-OCH 3 32 µg plus E 2 . Twenty-four hours after treatment, egg transport was assessed as described.
The mean number of eggs recovered from the oviducts of control group was of 8·6 1·1 (n=4) while in the group treated with E 2 it was 1·5 0·7 (n=3). In the group treated with ET-18-OCH 3 plus E 2 the mean number of eggs was 2·5 1·9 (n=4).
Effect of ET-18-OCH 3 on IP3 level in the oviduct
Here we verified that intrabursal administration of ET-18-OCH 3 effectively inhibited oviductal IP3 levels. A total of 16 rats were injected with ET-18-OCH 3 32 µg into one ovarian bursa and with saline in the contralateral bursa, and 6 h later oviducts were excised and processed to determine IP3 levels as described.
The level of IP3 was decreased in the oviducts treated with PLC inhibitor (0·08 0·01 pmol/oviduct, n=4) but not in the contralateral oviduct treated with saline (0·9 0·1 pmol/oviduct, n=4).
Effect of PD98059 on MAPK activity in the oviduct
Here we verified that intrabursal administration of PD98059 effectively inhibited oviductal MAPK activity. A total of 16 rats were injected with PD98059 50 µg into one ovarian bursa and with saline in the contralateral bursa, and 6 h later oviducts were excised and processed to determine MAPK activity as described.
The MAPK activity was decreased in the oviducts treated with MAPK inhibitor (0·09 0·02 OD 450 nm, n=4) but not in the contralateral oviduct treated with saline (0·60 0·07 OD 450 nm, n=4).
Effect of E 2 on IP3 levels in the oviduct
This experiment determined whether E 2 administration increases IP3 levels in the oviduct. A total of 36 animals on day 1 of the cycle were treated with vehicle or E 2 and 1, 3 or 6 h after treatment their oviducts were excised and processed to determine IP3 levels as described. This experiment consisted of 3 replicas.
The basal level of IP3 in the oviduct ranged from 0·30 0·04 to 0·60 0·08 pmol/oviduct. Oestradiol administration increased 10-12 times the IP3 levels measured at 1 and 6 h after treatment, but had no effect at 3 h (Figure 2) .
Effect of E 2 on MAPK phosphorylation in the oviduct
This experiment determined whether E 2 administration affects the level of phosphorylated MAPK p44/42 in the oviduct. A total of 16 animals on day 1 of the cycle were treated with E 2 and 0, 1, 3 or 6 h after treatment their oviducts were excised and processed to determine the level of phophorylated MAPK p44/42 as described. This experiment consisted of two replicas. Figure 3 shows that immunoblots of phosphorylated MAPK p44/42 of whole oviducts did not reveal any specific band compared with positive controls, although total MAPK p42 was present.
Effect of E 2 and/or ET-18-OCH 3 on oviductal PKA activity
Here we determined whether exogenous E 2 and/or inhibition of PLC-IP3 cascade affects oviductal PKA activity. A total of 28 animals on day 1 of the cycle were divided into four treatment groups: 1) vehicle plus propylene glycol; 2) ET-18-OCH 3 32 µg i.b. plus propylene glycol; 3) vehicle plus E 2 and 4) ET-18-OCH 3 plus E 2 . Previously we have shown that E 2 increases cAMP levels in rat oviducts at 3 h after treatment . Therefore, in this experiment PKA activity in the oviduct was assessed at 3·5 h after treatment as described. Replicas of this experiment are stated in Figure 4 . In order to confirm that PLC-IP3 signalling was inhibited following treatment with PLC inhibitor and E 2 , another 12 animals were divided into two treatment groups: 1) vehicle plus propylene glycol and 2) ET-18-OCH 3 plus E 2 , and 3·5 h later oviductal IP3 level was measured as described. The results are shown in Figure 4 . The mean PKA activity ( S.E.) in oviducts of the control group was 10·8 0·2 mU/µg protein, while in the group treated with E 2 it was 46·1 10·2 mU/ug protein. Local administration of the PLC inhibitor affected neither basal PKA activity (13·4 1·5 mU/µg protein) nor the E 2 -induced PKA increase (32·3 5·9 mU/µg protein) although it caused a 5-fold decrease in IP3 levels (vehicle+propylene glycol, 1·1 0·2 pmol/oviduct; ET-18-OCH 3 +E 2 , 0·02 0·02 pmol/oviduct, n=3).
Effect of specific cAMP-PKA signalling pathway inhibitor (SQ22536) on oviductal IP3 levels after E 2 administration
Here we assessed whether inhibition of cAMP-PKA signalling cascade affects the level of IP3 in the oviduct following treatment with E 2 . A total of 24 animals on day 1 of the cycle were divided into four treatment groups: 1) vehicle plus propylene glycol; 2) SQ22536 30 µg i.b. plus propylene glycol; 3) vehicle plus E 2 and 4) SQ22536 plus E 2 . Six hours after treatment, IP3 levels in the oviduct were assessed as described. This experiment consisted of four replicas.
The results are shown in Figure 5 . The IP3 levels in the oviducts of the control group were 0·80 0·08 pmol/ oviduct, while in the group treated with E 2 they were 5·20 0·07 pmol/oviduct. Local administration of the adenylyl cyclase inhibitor did not affect basal IP3 levels (0·80 0·09 pmol/oviduct), although it completely blocked the E 2 -induced IP3 increase (1·30 0·86 pmol/oviduct).
Effect of specific cAMP-PKA signalling pathway activator (Forskolin) on oviductal IP3 levels
Here we assessed whether activation of cAMP-PKA cascade affects the level of IP3 in the oviduct. A total of Figure 2 Inositol triphosphate levels in the oviducts of rats on day 1 of the oestrous cycle. At 1, 3 or 6 h after s.c. injection of vehicle (V) or 1 g oestradiol (E 2 ), oviducts were removed and IP3 levels were measured by a radioreceptor assay using IP3 from rabbit brain plasma membrane as standard. This experiment consisted of three replicas for each treatment group. Means with different letters are significantly different from each other (P<0·05). See Materials and Methods section for explanation of the assay.
Figure 3
Immunoblot of phosphorylated MAPK p44/42 (p-MAPK p44/42) or MAPK p42 of rat oviducts on day 1 of the oestrous cycle. At 0, 1, 3 or 6 h after s.c. injection of 1 g oestradiol (E 2 ), oviducts were removed and their proteins were subjected to SDS-PAGE followed by western blot with anti p-MAPK p44/42 or MAPK p42 antibodies. Note that the immunoblot did not reveal any specific band compared with positive control (MCF-7), although total MAPK p42 was present. eight animals on day 1 of the cycle were divided into two treatment groups: 1) DMSO and 2) Forskolin. Three hours after treatment, IP3 levels in the oviduct were assessed as described. This experiment consisted of three replicas.
The IP3 levels in oviducts of the control group were 0·59 0·22 pmol/oviduct, while Forskolin significantly increased the level of IP3 to 1·37 0·09 pmol/oviduct.
Discussion
Oestrogens elicit a variety of cellular responses through genomic and nongenomic pathways. Previously, we demonstrated that E 2 accelerates oviductal oocyte transport in cycling rats through a nongenomic pathway, which requires activation of cAMP-PKA signalling cascade . Here, we report that PLC-IP3 is a functional component of this E 2 nongenomic pathway, which is located downstream of the cAMP-PKA signalling cascade.
IP3 levels increased in the rat oviduct following E 2 treatment, suggesting that PLC activation is involved in accelerated oviductal transport induced by E 2 . Indeed blockade of PLC by ET-18-OCH 3 suppressed the E 2 -induced egg transport acceleration in a dose-dependent manner. These findings indicate unequivocally that PLC-IP3 signalling cascade is another component in the nongenomic pathway by which E 2 accelerates egg transport. This is in keeping with findings in other organs or cell lines. It has been documented that an increase in the turnover of inositol lipids is one mechanism used by E 2 to elicit nongenomic actions (Lössel et al. 2003) . The initial event is the hydrolysis of phosphatidylinositol 4,5-bisphosphate, a reaction catalyzed by a phosphoinositidespecific PLC, which generates two intracellular secondary messengers, IP3 and 1,2-diacylglycerol. Binding of IP3 to specific receptors on the endoplasmic reticulum mobilises intracellular calcium, which results in increased phosphorylation of proteins (Martin 1991) . In female rat osteoblasts, E 2 causes a 5-60 fold increase in the concentration of intracellular Ca 2+ by activation of PLC-and subsequent formation of IP3 (Le Mellay 1997). Singh and Gupta (1997) have shown that E 2 increases the metabolism of phosphoinositol lipids as well as production of inositol phosphates in rat vaginal epithelial cells independently of mRNA and protein synthesis. On the other hand, oestrogen addition to a hepatoma cell line HEPG2 causes rapid increase of IP3 production (Marino 1998) . Our findings show that a nongenomic action of E 2 mediated by PLC-IP3 is also present in the mammalian oviduct. Oestradiol increased oviductal IP3 levels at 1 and 6 h but not at 3 h after administration. This oscillating pattern suggests that the first increase is a direct response to E 2 and the second increase is in response to downstream intracellular changes. Alternatively, the two increases may be taking place each one in different cell types, e.g. epithelium and muscle.
Phospholipase C activation also produces 1,2-diacylglycerol with subsequent increased PKC activity (Martin 1991) . Furthermore, PKC activation is necessary for E 2 -induced oviductal protein phosphorylation . However, we have previously demonstrated that specific PKC inhibitors did not block the E 2 -induced egg transport acceleration , indicating that PLC-PKC signalling pathway is not involved in the nongenomic pathway by which E 2 accelerates oviductal egg transport.
The MAPK family is a conserved network of signal transduction enzymes that are activated by phosphorylation (Cobb & Goldsmith 1995) . Nongenomic activation of MAPK by E 2 has been reported in several cell systems (Chaturvedi & Sarkar 2004 , Sengupta et al. 2004 , Wade & Dorsa 2003 . However, we found that E 2 did not activate MAPKp44/42 and that inhibition of MAPK activity by PD98059 did not block the effect of E 2 on egg transport. These results indicate that the MAPK signalling pathway is not regulated by E 2 in the rat oviduct and that this cascade is not involved in the effect of E 2 on oviductal transport in cycling rats.
With the purpose of demonstrating the efficacy of PLC and MAPK inhibitors in our experimental design, we also measured IP3 levels and MAPK activity in the rat oviduct after intrabursal administration of ET-18-OCH3 and PD98059, respectively. Our results showed that IP3 levels and MAPK activity were decreased in oviducts treated with inhibitors, but not in the contralateral oviduct treated with saline. In addition, we determined that intrabursal administration of ET-18-OCH 3 in a dose that completely blocked E 2 -induced egg transport acceleration was unable to exert this effect when it was administered systemically.
All these results clearly demonstrate that these inhibitors effectively blocked the PLC-IP3 and MAPK signalling cascades in the oviduct and that their effects given intrabursally were due to local rather than systemic action.
We found that inhibition of cAMP-PKA signalling pathway by SQ 22536, at a concentration that blocks the E 2 -induced egg transport acceleration , blunted the IP3 level increase induced by E 2 , while inhibition of PLC-IP3 signalling pathway by ET-18-OCH 3 had no affect on the E 2 -induced PKA activity. Furthermore, activation of adenylyl cylase by Forskolin, at a concentration that accelerates oviductal egg transport increased oviductal IP3 levels. Thus, activation of PLC-IP3 by E 2 requires previous stimulation of cAMP-PKA, showing that both pathways are coupled in a directional sequence. Interaction between cAMP-PKA and PLC-IP3 signalling pathways, in response to neurotransmitters, prostaglandins or neuropeptides has been identified in nonvascular smooth muscle (for review see Abdel-Latif 2001), submandibular acinar cells (Martinez & Zhang 1998) or in osteoblast-like MC3T3-E1 cells (Kozawa et al. 1992) . According with our previous results and those shown in this paper we propose a model indicating that the nongenomic pathway utilised by E 2 to accelerate oviductal transport of oocytes in cycling rats involves successive activation of the cAMP-PKA and PLC-IP3 signalling cascades (Figure 6 ). Most of the literature describing the nongenomic actions of E 2 is limited to report changes in the regulation of specific molecules such as MAPK, IP3, AMPc, etc. in specific cell phenotypes, without clear linkage to physiological processes (reviewed in Lössel & Wehling 2003) . However, the evidence presented here highlights a nongenomic action of E 2 that is crucial in regulating a complex physiological process accomplished by an entire organ composed of diverse cell phenotypes.
In summary we conclude that PLC-IP3, but not MAPK, signalling pathway is involved in E 2 -induced egg transport acceleration and that a cAMP-PKA-PLC-IP3 cascade mediates the nongenomic action of E 2 in the rat oviduct. Figure 6 Schematic representation of an oestradiol nongenomic signalling pathway involved in accelerated oviductal egg transport in cycling rats. E 2 , oestradiol; ER, oestrogen receptor; AC, adenylyl cyclase; ATP, adenosin triphosphate; cAMP, cyclic adenosin monophosphate; PKA, protein kinase A; PIP 2 , phosphatidylinositol 4,5-bisphosphate; IP3, inositol triphosphate; ICI 182780, antiestrogen; SQ 22536, adenylyl cyclase inhibitor; Forskolin, adenylyl cyclase activator; ET-18-OCH 3 ,phospholipase C inhibitor; Rp-cAMP, protein kinase A inhibitor. The effects of ICI 182780, SQ 22536, Forskolin and Rp-cAMP on E 2 -induced egg transport acceleration were described by Orihuela et al. (2003) . Note that ER is depicted both in the cytosol and bound to the cell membrane. The actual location of the ER involved in nongenomic actions of E 2 is still unresolved (Lössel & Wehling 2003) .
